CTLA4 and neoplasm: In mouse models, anti-PD-1 monotherapy or combination therapy with anti-CTLA-4 significantly increased the size and number of TLS and enhanced their microanatomical organization into distinct T cell and B cell/FDC regions [75].This observation suggests that ICB has a strong impact on tumor-associated TLS and may enhance antitumor immune responses by increasing the number and size of TLS.